Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,267 across all filing types
Latest filing 2019-04-29 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
As required under Regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we furnish herewith a Certificate issued by the Practicing Company Secretary ....
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding the transfer of securities for the period October 1, 2018 to March 31, 2019. It is a compliance certificate from a Practicing Company Secretary confirming that the company has complied with the regulation on share transfers. The document is not a full financial report, earnings release, or management discussion, but rather a regulatory compliance certificate related to share transfer processes. It is not an announcement of a report but the certificate itself. This fits best under Regulatory Filings (RNS) as it is a regulatory compliance document that does not fit other specific categories like Director's Dealing or Share Issue. The document length is short (2963 characters), but it contains the certificate text itself, not just an announcement. Therefore, the appropriate classification is Regulatory Filings (RNS).
2019-04-29 English
Pursuant to Regulation 39(3) of SEBI (LODR) Regulations, 2015, the Company is intimating the request received relating to Loss of share certificate and issue of duplicate share certificate ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges notifying them about the loss of original share certificates and the request for issuance of duplicate share certificates. It includes details of the share certificates reported lost and is signed by the authorized signatory of the registry management services. The content is about share certificate replacement and notification to exchanges, not a financial report or earnings release. It does not contain financial data or management discussion. It is a regulatory announcement related to share certificates under LODR regulations, which fits best under Regulatory Filings (RNS). The document length is short and it is not an announcement of a report publication, so RPA is not appropriate.
2019-04-26 English
This is to certify that, Integrated Registry Management Services Private Limited are the Company's Registrar and Transfer Agents and that all activities in relation to both the physical ....
Regulatory Filings Classification · 95% confidence The document consists of certificates under Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, confirming that the company's Registrar and Transfer Agents maintain share transfer activities. It is a formal certification letter addressed to stock exchanges, with no financial data, no report content, and no announcement of voting results or management changes. The document is short (3117 characters) and primarily serves as a regulatory compliance certificate. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance-related certificate rather than a financial report or announcement.
2019-04-12 English
Disc. under Reg.30 of SEBI (SAST) Reg.2011
Major Shareholding Notification Classification · 100% confidence The document is a disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. It details the shareholding of the promoter AstraZeneca Pharmaceuticals AB in AstraZeneca Pharma India Limited as of March 31, 2019. This type of filing corresponds to a notification of changes in significant share ownership levels, which matches the definition of Major Shareholding Notification (MRQ). The document is not an annual report, earnings release, or any other report type but a regulatory disclosure about shareholding changes.
2019-04-11 English
Pursuant to Regulation 39(3) of SEBI (LODR) Regulations, 2015, the Company is intimating the request received for Loss of share certificate and issue of duplicate share certificate in respect ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding the loss of share certificates and the request for issuance of duplicate share certificates. It details specific folio numbers, certificate numbers, and share quantities. The content is about administrative handling of share certificates and notifying the exchanges about the subdivision of face value of shares. There is no financial data, no report or presentation, no voting results, no management or board changes, no earnings or audit information. This is a regulatory announcement related to share certificate handling under LODR regulations. The document is short (2028 characters) and is a formal notification to exchanges. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2019-03-20 English
This is to inform you that on March 13, 2019, the Board of the Directors of the Company has appointed Ms. Weiying Sarah Wang (DIN: 08369289) as an Additional Director (Non-Executive) on ....
Board/Management Information Classification · 100% confidence The document is a formal letter addressed to stock exchanges announcing the appointment of Ms. Sarah Wang as an Additional Director on the Board of Directors of AstraZeneca Pharma India Ltd. It includes a brief profile of the appointee and is dated March 14, 2019. There is no financial data, report, or regulatory filing content beyond the management change announcement. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2019-03-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.